ERCC2 and cervical cancer: In contrast, the ERCC2 Asp312Asn polymorphism did not elevate the risk of gynecologic neoplasms, and the recessive gene variant was even protective against cervical cancer (AA vs GA+GG : OR 0.53, 95%CI 0.34-0.83, P=0.005).